Legal & General Group PLC Nurix Therapeutics, Inc. Transaction History

Legal & General Group PLC

$431 Billion
Q3 2025

A detailed history of Legal & General Group PLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 82,917 shares of NRIX stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,917

Previous 62,420 32.84%

Holding current value

$1.06 Million

Previous $710,000 7.89%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$8.24 - $13.18 $168,895 - $270,150	20,497 Added 32.84%	82,917 $766,000
Q2 2025 Aug 12, 2025	BUY	$8.81 - $12.79 $33,486 - $48,614	3,801 Added 6.48%	62,420 $710,000
Q1 2025 May 15, 2025	SELL	$11.88 - $20.15 $21,360 - $36,229	-1,798 Reduced 2.98%	58,619 $696,000
Q4 2024 Feb 13, 2025	SELL	$18.64 - $28.14 $92,473 - $139,602	-4,961 Reduced 7.59%	60,417 $1.14 Million
Q3 2024 Feb 28, 2025	SELL	$18.93 - $25.69 $9,805 - $13,307	-518 Reduced 0.86%	59,899 $1.34 Million

Q3 2024 Nov 14, 2024	BUY	$18.93 - $25.69 $170,729 - $231,698	9,019 Added 16.0%	65,378 $1.47 Million
Q2 2024 May 29, 2025	BUY	$12.02 - $21.3 $530,538 - $940,139	44,138 Added 654.67%	50,880 $1.06 Million
Q2 2024 Aug 14, 2024	BUY	$12.02 - $21.3 $596,396 - $1.06 Million	49,617 Added 735.94%	56,359 $1.18 Million
Q1 2024 May 29, 2025	SELL	$7.77 - $15.66 $403,084 - $812,393	-51,877 Reduced 88.5%	6,742 $99,000
Q1 2024 May 14, 2024	SELL	$7.77 - $15.66 $1,196 - $2,411	-154 Reduced 2.23%	6,742 $99,000
Q4 2023 May 29, 2025	SELL	$4.25 - $10.71 $219,822 - $553,953	-51,723 Reduced 88.24%	6,896 $71,000
Q4 2023 Feb 15, 2024	SELL	$4.25 - $10.71 $106,602 - $268,638	-25,083 Reduced 78.44%	6,896 $71,000
Q3 2023 Nov 14, 2023	SELL	$7.86 - $10.08 $4,393 - $5,634	-559 Reduced 1.72%	31,979 $251,000
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $156,008 - $238,136	17,932 Added 122.77%	32,538 $325,000
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $5,221 - $8,088	610 Added 4.36%	14,606 $129,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $7,069 - $10,461	717 Added 5.4%	13,996 $153,000
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $13,636 - $21,909	1,106 Added 9.09%	13,279 $173,000
Q2 2022 Aug 22, 2022	BUY	$7.88 - $14.82 $25,342 - $47,661	3,216 Added 35.9%	12,173 $154,000
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $129 - $296	-10 Reduced 0.11%	8,957 $126,000
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $1,400 - $1,828	53 Added 0.59%	8,967 $259,000
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $119,023 - $192,292	5,241 Added 142.69%	8,914 $267,000
Q2 2021 Aug 12, 2021	BUY	$24.21 - $35.89 $18,084 - $26,809	747 Added 25.53%	3,673 $98,000
Q1 2021 May 17, 2021	BUY	$26.98 - $50.17 $33,671 - $62,612	1,248 Added 74.37%	2,926 $90,000
Q4 2020 Feb 12, 2021	BUY	$22.85 - $48.44 $9,916 - $21,022	434 Added 34.89%	1,678 $55,000
Q3 2020 Nov 13, 2020	BUY	$16.05 - $34.91 $19,966 - $43,428	1,244 New	1,244 $43,000

Others Institutions Holding NRIX

# of Institutions

184

Shares Held

77.6M

Call Options Held

99.8K

Put Options Held

11.3K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $603M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Nurix Therapeutics, Inc. Transaction History